David Gryska

David Gryska has served as a director of the Company since June 21, 2023. Mr. Gryska previously served as Executive Vice President and Chief Financial Officer of Incyte Corporation from 2014 until his retirement in December 2018. Additionally, Mr. Gryska served as Chief Operating Officer and a director of Myrexis, Inc. in 2012. From 2006 to 2010, Mr. Gryska served as Senior Vice President and Chief Financial Officer of Celgene Corporation. From 2004 to 2006, Mr. Gryska was a principal at Strategic Consulting Group, where he provided strategic consulting to early-stage biotechnology companies. Previously, Mr. Gryska served at Scios Inc. as Senior Vice President and Chief Financial Officer from 2000 to 2004 and as Vice President of Finance and Chief Financial Officer from 1998 to 2000. From 1993 to 1998, Mr. Gryska served as Vice President, Finance and Chief Financial Officer at Cardiac Pathways Corporation. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst & Young LLP in California. Mr. Gryska has served on the board of directors of Forte Biosciences, Inc. since January 2023. Mr. Gryska previously served on the boards of directors of Seagen Inc. from 2005 through its acquisition by Pfizer in December 2023; Aerie Pharmaceuticals from 2018 through its acquisition by Alcon in November 2022; GW Pharmaceuticals from 2020 through its acquisition by Jazz Pharmaceuticals in May 2021; and PDL BioPharma from 2014 to 2020.

Mr. Gryska holds a Bachelor of Arts in Accounting and Finance from Loyola University and an MBA from Golden Gate University.